课题基金 / 基金详情

Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models

Molecular Determinants of Statin Efficacy and Adverse Effects in Cellular Models
细胞模型中他汀类药物疗效和不良反应的分子决定因素
批准号:
9139486
负责人:
Marisa Wong Medina
金额:
$105.74万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressAdverse effectsAdverse eventAmericanBiological MarkersBiological ModelsBlood CellsCaliforniaCandidate Disease GeneCardiovascular systemCell LineCell modelCholesterolClinicalClinical TrialsCollaborationsCoronaryCoronary heart diseaseDNADataDevelopmentDiabetes MellitusDrug PrescriptionsEnzymesEtiologyEventFutureGene ChipsGene ExpressionGenesGeneticGenetic screening methodGenotypeGlucoseGoalsGuidelinesHumanHuman Cell LineIn VitroIncubatedIndividualInformaticsInsulinIsoenzymesKnowledgeLDL Cholesterol LipoproteinsLeadLibrariesLipidsMeasurementMeasuresMetabolicModelingMolecularMuscleMyopathyNon-Insulin-Dependent Diabetes MellitusOutcomePDH kinaseParticipantPathway interactionsPatientsPeptidesPharmacogeneticsPharmacogenomicsPhenotypePlasmaPopulationPreventionProductivityPropertyQuantitative Trait LociReportingRiskRoleSimvastatinSystemTestingTherapeuticToxic effectTranscriptTreatment outcomeUntranslated RNAValidationVariantadverse outcomebasebiomarker identificationblood glucose regulationc newcardiovascular disorder preventioncardiovascular disorder riskcase controlcholesterol controlclinical practicecohortgenetic associationgenetic signaturegenetic variantgenome wide association studygenome-wideglucose metabolismimprovedin vivointer-individual variationknock-downlymphoblastoid cell linemetabolomicsnovelnovel markernovel therapeutic interventionoverexpressionpopulation basedprecision medicinepreventresponsetraittranscriptometranscriptome sequencingtranscriptomicsvalidation studies

项目摘要

项目成果

Marisa Wong Medina的其他基金

相似基金

相关文献

中文摘要
翻译
项目1:总结 近一半40-75岁的美国人有资格接受他汀类药物预防心血管疾病 根据AHA/ACC新的胆固醇管理指南,可降低心血管疾病的风险。然而,有很高的比例 接受他汀类药物治疗的患者中,仍有患心血管疾病的风险,而且他汀类药物存在显著的不良反应。 治疗,最显著的是肌病和新发糖尿病。目前,有关这方面的信息有限 这些不同的结果是有根据的,预测它们的遗传或其他生物标记物很少。因此,有 需要制定他汀类药物治疗的精准医学标准。使用In的转录转录分析 他汀类药物临床试验参与者的辛伐他汀或假暴露的淋巴母细胞系(LCLS) 先前发现了一些涉及调节他汀脂代谢效应的新基因 治疗。通过体外实验获得了这些基因生物学和临床作用的支持证据。 基因敲除和过度表达研究以及与两位候选人相关的SNP的鉴定 基因表达(EQTL)和体内他汀类药物的降脂反应。当前的总目标 项目是利用这种一般方法来识别他汀类药物的新生物标记物和/或决定因素 临床结果,即预防心血管疾病的有效性和他汀类药物诱导的肌病和2型的风险 糖尿病。在目标1中,我们将利用北加州凯撒永久医院(KPNC)的后临床核心来 从接受他汀类药物治疗的患者获得LCLS:1)有重大不良冠状动脉事件(MACE);2)他汀类药物诱导 肌病;或3)新发的2型糖尿病;以及每种结果的匹配对照组。LCLS将是 暴露于辛伐他汀与假的相比,转录和代谢测量将被用来识别 他汀类药物疗效和不良反应的新型细胞生物标志物。在AIM 2中,与项目3和 信息学核心,与这些生物标记物相关的DNA变体将被识别和测试 使用来自一个非常大的KPNC队列的基因数据与MACE和他汀类药物不良反应的相关性 全基因组的基因分型数据是可用的。最后,在目标3中,与他汀类药物反应相关的新基因 在本项目内或整个中心内确定的项目将使用假设驱动进行功能验证 在适当的细胞模型中使用敲除和过度表达的研究。总体而言,我们预计 完成这些目标将导致识别和验证新的生物标志物(转录本、代谢物、 和/或单核苷酸多态)预测他汀类药物的治疗结果,这可以在开发未来的治疗方法中增加价值 指导方针。此外,通过扩展我们对变异的潜在分子决定因素的知识, 他汀类反应,在这个项目和整个邮政中心采用的“系统”方法可能会导致 开发新的治疗方法以增加他汀类药物的益处和/或降低其风险。
英文摘要
PROJECT 1: SUMMARY Nearly half of Americans between 40-75 yr are eligible for statin treatment for prevention of cardiovascular disease (CVD) according to new AHA/ACC guidelines for cholesterol management. However, a high proportion of statin-treated patients remain at risk for CVD, and there is significant potential for adverse effects of treatment, most notably myopathy and new onset diabetes. Currently, there is limited information regarding the basis for these varying outcomes and very few genetic or other biomarkers for their prediction. Thus, there is need for the development of precision medicine standards for statin therapy. Using transcriptomic analysis of in vitro simvastatin or sham exposed lymphoblastoid cell lines (LCLs) from participants in a statin clinical trial, we previously identified a number of novel genes implicated in modulating the lipid metabolic effects of statin treatment. Supporting evidence for the biologic and clinical roles of these genes was obtained by in vitro knock-down and overexpression studies as well as by identification of SNPs associated with both candidate gene expression (eQTLs) and in vivo statin lipid-lowering response. The overall objective of the present project is to utilize this general approach to identify novel biomarkers and/or determinants of statin clinical outcomes, namely efficacy for CVD prevention, and risk of statin-induced myopathy and type 2 diabetes. In Aim 1 we will utilize the POST Clinical Core at Kaiser Permanente Northern California (KPNC) to obtain LCLs from statin treated patients with: 1) a major adverse coronary event (MACE); 2) statin-induced myopathy; or 3) new onset type 2 diabetes; as well as matched controls for each outcome. The LCLs will be exposed to simvastatin vs. sham and transcriptomic and metabolomic measurements will be used to identify novel cellular biomarkers for statin efficacy and adverse effects. In Aim 2, in collaboration with Project 3 and the Informatics Core, DNA variants associated with these biomarkers will be identified and tested for association with MACE and statin adverse effects using genotype data from a very large KPNC cohort in which genome-wide genotype data are available. Finally, in Aim 3, novel genes associated with statin response identified within this Project or throughout the Center will be functionally validated using hypothesis-driven studies employing knock-down and overexpression in appropriate cell models. Overall, we anticipate that the completion of these aims will lead to identification and validation of new biomarkers (transcripts, metabolites, and/or SNPs) predictive of statin treatment outcomes that can add value in developing future therapeutic guidelines. Moreover, by expanding our knowledge of the underlying molecular determinants of variation in statin response, the "systems" approach employed in this project and throughout the POST Center could lead to development of new therapeutic approaches for augmenting statin's benefits and/or reducing its risks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TMEM55B as a molecular determinant of NAFLD
The Role of Phosphatidylinositides in Lipid Metabolism
Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake
Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake
海外基金